非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展

Advance in MicroRNAs and EGFR-TKIs Secondary Resistance Research in Non-small Cell Lung Cancer

近年来,在非小细胞肺癌(non-small cell lung cancer,NSCLC)靶向治疗中,尤其是伴有表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的患者,EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)越来越多地进入到临床治疗,但EGFR-TKI耐药的产生不仅影响药物敏感性,甚至出现疾病进展,成为制约其疗效的主要瓶颈。微小RNA(microRNAs,mi RNAs)是一种非编码蛋白的RNA,参与转录后水平基因的表达调控,最近研究发现,miRNAs参与了EGFR-TKIs耐药,影响肿瘤细胞对吉非替尼的敏感性。本文就NSCLC中mi RNAs与EGFR-TKIs继发性耐药之间的相关性研究进展做简要的综述。

In recent years, in non-small cell lung cancer （NSCLC） targeted therapy, especially in patients with epidermal growth factor receptor （EGFR） mutations, EGFR-tyrosine kinase inhibitors （TKI） more and more come into the clinical treatment, but EGFR-TKI resistance not only inlfuence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs （miRNAs） is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed brielfy advance in miRNAs and EGFR-TKIs secondary resis-tance research in NSCLC.